Making the discoveries that defeat cancer

  • Home »
  • Research »
  • Repository

  • Administrators Login

  • Repository Homepage
  • About the Repository
  • Browse the Repository
  • Search the Repository
  • Contribute an Article
  • Missing Publications
  • Repository Help

Olaratumab - really a breakthrough for soft-tissue sarcomas?

Tools
- Tools
+ Tools

Judson, I., van der Graaf, W. T. (2016) Olaratumab - really a breakthrough for soft-tissue sarcomas? NATURE REVIEWS CLINICAL ONCOLOGY, 13 (9). pp. 535-536. ISSN 1759-4774

Full text not available from this repository.

Abstract

In a recent study, the addition of olaratumab to doxorubicin chemotherapy for patients with soft-tissue sarcoma resulted in prolongation of progression-free survival by only 2.5 months, but an overall survival benefit of 11.8 months; the large disparity between these outcomes raises important questions. We discuss these results in relation to those of other trials, and the implications for sarcoma therapy.

Item Type: Editorial
Authors (ICR Faculty only): Judson, Ian and van der Graaf, Winette
All Authors: Judson, I., van der Graaf, W. T.
Additional Information: ISI Document Delivery No.: DU4HS Times Cited: 0 Cited Reference Count: 8 Judson, Ian van der Graaf, Winette T. 0 NATURE PUBLISHING GROUP NEW YORK NAT REV CLIN ONCOL
Uncontrolled Keywords: CONTROLLED PHASE-3 TRIAL
Research teams: ICR divisions > Cancer Therapeutics > Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)
ICR divisions > Clinical Studies > Sarcoma Clinical Trials
ICR divisions > Clinical Studies > Clinical and Translational Sarcoma
Depositing User: Barry Jenkins
Date Deposited: 18 Oct 2016 09:05
Last Modified: 18 Oct 2016 09:05
URI: http://publications.icr.ac.uk/id/eprint/15341

Actions (login required)

View Item View Item
The Royal Marsden - NHS foundation trust